Navigation Links
Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results
Date:8/21/2008

/p>

Equity Compensation Expense

Per Share (net of tax) $0.28 $0.15

Supplemental Sales Data. Sales for the fourth quarter and for the fiscal year 2008 increased to $15.0 and $53.8 million up from $10.5 and $44.9 million, respectively, in the prior fiscal year periods. Additional details are summarized below.

Three Months Fiscal Year

Ended Year over Ended Year over

June 30, Year % June 30, Year %

($ millions) 2008 2007 Change 2008 2007 Change

Endovascular

Products $1.6 $0.8 103% $6.2 $3.8 64%

Orthopaedic

Products $8.4 $6.0 39% $29.4 $21.8 35%

Cardiovascular

Products $4.2 $3.2 29% $15.9 $17.6 (10%)

Other Products $0.8 $0.5 65% $2.3 $1.7 33%

Total Net Sales $15.0 $10.5 42% $53.8 $44.9 20%

Guidance for Fiscal Quarter Ending September 30, 2008 (First Quarter of Fiscal 2009)

At this time the Company is increasing its earnings per share guidance for the first quarter of fiscal 2009 to a range of $0.37 to $0.38 per share, an increase of 131% to 138% compared to adjusted diluted earnings per share of $0.16 for the same period in fiscal year 2008. Previous guidance for the first quarter of fiscal year 2009 was $0.34 to $0.36 per share. This increase is primarily due to an anticipated increase in royalties and a reduction in operating expenses. Adjusted diluted earnings per share for the first quarter of fiscal year 2008 exclude after-tax charges of $2.2 million, or $0.17 per share, for the acceleration of stock awards and discontinuation of the Company's embolic protection platform. Including these items, the 2008 first quarter reported diluted
'/>"/>

SOURCE Kensey Nash Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Kensey Nash Corporation Announces Its Third Quarter 2008 Earnings Release Date and Teleconference
2. Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology
3. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
4. Kensey Nash to Participate in the Sidoti Fifth Annual Palm Beach Emerging Growth Institutional Investor Forum Conference
5. Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference
6. Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference
7. InstaCare Corp. Continues Turnaround & Reports 291% Revenues Increase in 2Q 2008
8. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
9. Expert Neurology Panel Weighs Impact of New Reports of PML in Multiple Sclerosis Patients on Tysabri
10. Arpida Reports Interim Results for Six Months to 30 June 2008
11. Rosetta Genomics Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 19, 2013   NineSigma , Inc., of ... following its launch, NineSights.com is now the ... for the worldwide community of innovators. From ... sustainability experts, NineSights stands out for its large community ... and technical disciplines, all vetted by NineSigma. The community ...
(Date:6/19/2013)... Atlanta (PRWEB) June 19, 2013 Today ... urged young people to become leaders in the greatest ... 9 billion people in 2050. Borel spoke at ... Conference in Atlanta, about urgent need for students ... that are local, science-based, sustainable and reached in collaboration ...
(Date:6/19/2013)... June 19, 2013 ... presents Innovative Drug Delivery Systems: ... Licensing Opportunities for Generic Pharmaceutical ... There are more than ... drugs approved all over the ...
(Date:6/19/2013)... India’s vast and growing population means ... up to a billion dollars per year by ... taking serious action to better regulate and oversee ... will examine:, ,     Recent changes in ... long term impacts ,     Foreseeable opportunities ...
Breaking Biology Technology:NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 2NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights 3DuPont Leader Calls for New Generation of Food Visionaries to Fight Hunger 2Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 2Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 3
... revolutionary surgical instrument system that is smaller in diameter than a ... implantation of the VerteLoc™ Minimally Invasive Spine Stabilization System and will ... Arizona starting on March 12, 2009. , ... Winston-Salem, ...
... In ClearTrial v2.7, the newest version of ... Portfolio Planning capability which enables clinical development ... into portfolio-level forecasts in minutes. The ... monthly resource demand, and timelines across a ...
... Enobia Pharma, an emerging Canadian biotech company ... disorders, today announced completion of target enrollment in ... a severe form of hypophosphatasia. Enobia is ... the treatment of this rare and often crippling ...
Cached Biology Technology:VGI Announces the Launch of DISMISS Instruments for the VerteLoc™ Minimally Invasive Spine Stabilization System 2ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability 2ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability 3ClearTrial Launches Version 2.7 of its Clinical Trial Operations Planning Software Featuring Advanced Portfolio Planning Capability 4Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia 2Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia 3
(Date:6/19/2013)... Medicines Agency (EMA) approved the modified adeno-associated virus ... for clinical use in the Western world. uniQure, ... for the treatment of a rare inherited metabolic ... approximately one or two out of one million ... the pancreas. Afflicted individuals carry a defect in ...
(Date:6/18/2013)... from the United Kingdom, the Energy Department,s National ... Kentucky have recently published a paper describing a ... Limnoria quadripunctata , commonly known as the ... they exhibit a relatively unique ability to produce ... to break down the biomass they eat. New ...
(Date:6/18/2013)... of Molecular Biology, has been honored as a ... Torrent is being recognized for his outstanding research, ... antimicrobial regions in proteins. Luis Rivas, Centro de ... algorithm to interrogate full genomes in order to ... results." , Torrent obtained his Ph.D. from ...
Breaking Biology News(10 mins):No danger of cancer through gene therapy virus 2Novel enzyme from tiny gribble could prove a boon for biofuels research 2The American Society for Microbiology honors Marc Torrent 2
... an inherited genetic basis for racial and ethnic disparities ... increased risk of relapse in young leukemia patients. The ... Research Hospital and the Children,s Oncology Group (COG). ... new marker of poor treatment outcome, researchers reported evidence ...
... N.C. Everyone knows chocolate is critical to a happy Valentine,s ... a heart happy the rest of the year. It,s a ... DOT1L enzyme, you could be at risk for some types of ... the University of North Carolina at Chapel Hill School of Medicine ...
... Reserve University have developed a little bomb that promises a ... an anti-cancer drug loosely attached to gold nanoparticles starts accumulating ... activated for an effective treatment within two hours. The same ... the tumor from the surface a far less effective ...
Cached Biology News:Native American ancestry linked to greater risk of relapse in young leukemia patients 2Native American ancestry linked to greater risk of relapse in young leukemia patients 3Just in time for Valentine's Day: UNC researchers identify a gene critical for heart function 2A loose grip provides better chemotherapy 2
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
Phospho-4E-BP1 (Thr37/46) (236B4) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
WTAP Antibody...
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: